-

02:10:32 AM

FBIO Stock News

FBIO - Fortress Biotech Inc

10/18/21 8:30 AM

Nasdaq : FBIO

conferences

Fortress Biotech to Participate in Dawson James Securities’ 6th Annual Small Cap Growth Conference

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced

RHEA-AI

neutral

10/13/21 7:29 PM

Nasdaq : FBIO

clinical trial

Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition

Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, with support from its licensing partner Sentynl Therapeutics, Inc. ("Sentynl"), a wholly owned subsidiary of Cadila

RHEA-AI

neutral

10/08/21 8:00 AM

Nasdaq : FBIO

clinical trial

Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition

Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease Overall survival significantly improved in patients treated with CUTX-101 Rolling submission of New Drug Application to the FDA for CUTX-101 planned to begin in fourth quarter of

RHEA-AI

neutral

10/06/21 8:00 AM

Nasdaq : FBIO

acquisition

Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical

RHEA-AI

neutral

10/05/21 8:30 AM

Nasdaq : FBIO

management

Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer

Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”) focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated

RHEA-AI

very positive

09/29/21 7:00 AM

Nasdaq : FBIO

acquisition

Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech

Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech 1 AstraZeneca intends to advance and accelerate the Phase 3 development of CAEL-101 for light chain (AL) amyloidosis HSR waiting period

RHEA-AI

positive

09/28/21 8:30 AM

Nasdaq : FBIO

conferences

Fortress Biotech to Participate in the Benzinga Healthcare Small Cap Conference

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced

RHEA-AI

neutral

09/09/21 8:30 AM

Nasdaq : FBIO

conferences

Fortress Biotech to Participate in Three September 2021 Investor Conferences

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced

RHEA-AI

neutral

08/16/21 4:01 PM

Nasdaq : FBIO

earnings

Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights

Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record Rolling NDA submission for CUTX-101 for the treatment of Menkes disease expected to begin in the second half of 2021 On track to report top-line results from registration-enabling study of

RHEA-AI

neutral

06/30/21 8:00 AM

Nasdaq : FBIO

Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea

Journey Medical Corporation (“Journey Medical”),

RHEA-AI

positive

FBIO Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.fortressbiotech.com
CeoLindsay Rosenwald
Security nameFortress Biotech Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees111
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2 Gansevoort St Fl 9
StateNew York
CityNew York
Zip10014-1667
CountryUS
Phone17816524500

FBIO Description:

Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company that was ranked in Deloitte's 2019 and 2020 Technology Fast 500™, annual rankings of the fastest- growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high- potential marketed and development-stage drugs and drug candidates. The company has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children's Research Hospital and Nationwide Children's Hospital.